Periodic Reporting for period 1 - VACCELERAID (A novel vaccine technology leading to accelerated availability of vaccines and improved delivery)
Reporting period: 2016-11-01 to 2017-04-30
Long-term and overall objective of VACCELERAID:
(1) To validate and commercialize a novel technology platform for faster, safer, adjuvant-free, more efficient and more cost-effective manufacturing and delivery of vaccines for prevention of infectious diseases.
(2) Geza Ad Ltd. (GZA) aims at marketing approval of a novel influenza vaccine resulting from said technology. The technology has further potential for use in other indications.
(3) The business model of GZA will be based upon co-development and licensing agreements with established pharma companies active in the vaccine sector. GZA will receive milestone payments and royalties based on their global vaccine sales.
Furthermore, input from experienced regulatory professionals was obtained and a draft regulatory strategy aiming at marketing approval for the novel influenza vaccine starting in the EU was elaborated (including type of early and continued interaction with regulatory authorities and timing thereof).
Two quality control assays to monitor efficiency & reproducibility of said technology were developed and methods for most efficient targeting/delivery of a vaccine were fine-tuned.
GZA has completed this phase 1 feasibility study successful. The results strongly support continuation of the project. In any case, GZA is planning to submit a phase 2 proposal to be able to continue VACCELERAID with EU support. In particular, the very high innovation and extremely attractive commercial potential of the VACCELERAID technology – later to be exemplified by full development of a novel influenza vaccine – have been underpinned even further.
The improvement potential, i.e. the benefits for all users are improved cost-efficiency and competitiveness (e.g. significantly reduced costs as compared to egg-dependent manufacturing; manufacturers able to serve sudden vaccine demands first are more likely to receive contracts).
In addition, the technology has a strong upside potential since the technology might be used for delivery of other vaccines.